SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of November, 2006
SkyePharma PLC
SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.
Form 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______
For Immediate Release 14 November, 2006
SkyePharma PLC
SKYEPHARMA APPOINTS NEW FINANCE DIRECTOR
LONDON, ENGLAND, 13 November 2006 - SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) announces today that Mr. Donald Nicholson is standing
down as Finance Director with immediate effect and will be leaving the Company to pursue a new phase in his career. Mr. Peter Grant
has been appointed Finance Director in his place.
Peter, 51, is a Chartered Accountant with a MA (Hons), Mathematics from Oxford University. He qualified with the firm of Peat,
Marwick, Mitchell & Co. in 1979. With over 25 years of finance and management experience in UK companies, including nine years at
listed company board level, Peter brings extensive experience as a Finance Director at Molins PLC, Worldpay Group PLC and Eurodis
Electron PLC where he worked as Group Finance Director until January 2005. Most recently, Peter had been interim CEO at Voice
Commerce Group, a position he held until May 2006.
Donald joined SkyePharma in February 1996 and was appointed Finance Director in March 1997.
Jerry Karabelas, Chairman of SkyePharma, said:
"On behalf of the whole Board and staff, I would like to thank Donald for his significant contribution and commitment to the Company
over the past ten years. We wish him well for the future.
"We are very pleased to have recruited someone of Peter's calibre to fill the key role of Finance Director. He has played a
significant role in streamlining operations, developing new business activities and financing initiatives. He will join our new
management team of Frank Condella, CEO and Ken Cunningham, COO and will be of great assistance in moving the Company forward through
this important stage in its development."
Disclosure under section 9.6.13 of the Listing Rules:
Mr Grant resigned from the board of Eurodis Electron PLC in January 2005 for family health reasons. In March 2005 a major franchiser
gave notice of termination of its relationship with the group, and in July 2005 the lead finance provider reduced the facilities and
the company went into administration.
There are no other disclosures under section 9.6.13 of the Listing Rules.
For further information please contact:
SkyePharma PLC UK + 44 207 491 1777
Frank Condella, Chief Executive Officer
Ken Cunningham, Chief Operating Officer
Buchanan Communications UK + 44 207 466 5000
Tim Anderson / Mark Court / Rebecca Skye Dietrich
The Trout Group US + 1 617 583 1308
Seth Lewis
Notes for editors
About SkyePharma
SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use
and more effective drug formulations. There are now eleven approved products incorporating SkyePharma's technologies in the areas of
oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, visit
www.skyepharma.com.
Certain statements in this news release are forward-looking statements and are made in reliance on the safe harbour provisions of the
U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectations reflected in these forward-looking
statements are reasonable, it can give no assurance that these expectations will materialize. Because the expectations are subject to
risks and uncertainties, actual results may vary significantly from those expressed or implied by the forward-looking statements
based upon a number of factors, which are described in SkyePharma's 20-F and other documents on file with the SEC. Factors that could
cause differences between actual results and those implied by the forward-looking statements contained in this news release include,
without limitation, risks related to the development of new products, risks related to obtaining and maintaining regulatory approval
for existing, new or expanded indications of existing and new products, risks related to SkyePharma's ability to manufacture products
on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability to market products on a large scale to
maintain or expand market share in the face of changes in customer requirements, competition and technological change, risks related
to regulatory compliance, the risk of product liability claims, risks related to the ownership and use of intellectual property, and
risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obligation to revise or update any such
forward-looking statement to reflect events or circumstances after the date of this release.
END
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SkyePharma PLC
By: /s/ Douglas Parkhill
Name: Douglas Parkhill
Title:
Company Secretary
Date: November 14, 2006